Regression of Left Ventricular Hypertrophy: Lodestar to Stroke Prevention in the Treatment of Hypertension?

American Journal of Hypertension

Volumn 19, Issue 5, 2006, Pages 439-442

  Kizer, Jorge R ^a   Devereux, Richard B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; LOSARTAN; THIAZIDE DIURETIC AGENT;

AGE DISTRIBUTION; ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD PRESSURE MEASUREMENT; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE PREDISPOSITION; EDITORIAL; ELECTROCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE OXYGEN CONSUMPTION; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; LIFESTYLE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STROKE; TACHYCARDIA; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

ANTIHYPERTENSIVE AGENTS; CEREBROVASCULAR ACCIDENT; DISEASE PROGRESSION; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR;

EID: 33646104647     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2005.12.005     Document Type: Editorial

References (18)

1. Kjeldsen S.E., Julius S., Hedner T., and Hansson L. Stroke is more common than myocardial infarction in hypertension. analysis based on 11 major randomized intervention trials. Blood Press 10 (2001) 190-192
2. American Heart Association. Heart disease and stroke statistics-2004 update (2004), American Heart Association, Dallas
3. Samsa G.P., Matchar D.B., Goldstein L., Bonito A., Duncan P.W., Lipscomb J., Enarson C., Witter D., Venus P., Paul J.E., and Weinberger M. Utilities for major stroke. results from a survey of preferences among persons at increased risk for stroke. Am Heart J 136 (1998) 703-713
4. Straus S.E., Majumdar S.R., and McAlister F.A. New evidence for stroke prevention. Scientific review. J Am Coll Cardiol 288 (2002) 1388-1395
5. Prospective Studies Collaboration. Age-specific relevance of usual BP to vascular mortality. a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903-1913
6. Bikkina M., Levy D., Evans J.C., Larson M.G., Benjamin E.J., Wolf P.A., and Castelli W.P. Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study. J Am Coll Cardiol 272 (1994) 33-36
7. MacMahon S.W., Wilcken D.E.L., and Macdonald G.J. The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients. N Engl J Med 314 (1986) 334-339
8. Gottdiener J.S., Reda D.J., Massie B.M., Materson B.J., Williams D.W., and Anderson R.J. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 95 (1997) 2007-2014
9. Klingbeil A., Schneider M., Martus P., Messerli F.H., and Schmieder R.E. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115 (2003) 41-46
10. Levy D., Salomon M., D'Agostino R.B., Belanger A.J., and Kannel W.B. Prognostic impolications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 90 (1994) 1786-1793
11. Mathew J., Sleight P., Lonn E., Johnstone D., Pogue J., Yi Q., Bosch J., Sussex B., Probstfield J., and Yusuf S. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipirl. Circulation 104 (2001) 1615-1621
12. Okin P.M., Devereux R.B., Jern S., Kjeldsen S.E., Julius S., Nieminen M.S., Snapinn S., Harris K.E., Aurup P., Edelman J.M., Wedel H., Lindholm L.H., and Dahlof B. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. J Am Coll Cardiol 292 (2004) 2343-2349
13. Devereux R.B., Wachtell K., Gerdts E., Boman K., Nieminen M.S., Papademetriou V., Rokkedal J., Harris K., Aurup P., and Dahlof B. Prognostic significance of left ventricular mass change during treatment of hypertension. J Am Coll Cardiol 292 (2004) 2350-2356
14. Verdecchia P, Angeli F, Gattobigio R, Sardone M, Pede S, Reboldi GP: Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. Am J Hypertens (in press).
15. Iadecola C., and Gorelick P.B. Hypertension, angiotensin, and stroke. beyond blood pressure. Stroke 35 (2004) 348-350
16. Saba P.S., Roman M.J., Pini R., Spitzer M., Ganau A., and Devereux R.B. Relation of arterial pressure waveform to left ventricular and carotid anatomy in normotensive subjects. J Am Coll Cardiol 22 (1993) 1873-1880
17. Olsen M.H., Wachtell K., Neland K., Bella J.N., Rokkedal J., Dige-Petersen H., and Ibsen H. Losartan but no atenolol reduces carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood Press 14 (2005) 177-183
18. Okin P.M., Wachtell K., Devereux R.B., Harris K.E., Jern S., Kjeldsen S.E., Julius S., Lindholm L.H., Nieminen M.S., Edelman J.M., and Dahlof B. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in hypertensive patients. J Am Coll Cardiol 45 Suppl A (2005) 374A